Haleon plc Form 6-K Summary
Business Context and Reporting Period
Haleon plc filed a Form 6-K for July 2022, dated July 19, 2022. The filing contains a TR-1 notification of major holdings concerning Pfizer Inc. It is not a financial results filing and does not report an operating period or financial statements.
Financial and Ownership Metrics
- Pfizer reported total voting rights of 32.0% in Haleon, representing 2,955,063,626 voting rights.
- The position consisted of 2,364,050,902 ordinary shares, equal to 25.6% of voting rights, and 591,012,724 restricted ADRs, equal to 6.4%.
- No voting rights were reported through financial instruments.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes Versus the Prior Comparable Period
The notification states that Pfizer acquired or disposed of voting rights and crossed or reached the relevant threshold on July 17, 2022. A prior position is not provided in the filing, so the precise change in Pfizer’s ownership cannot be determined from the submitted text.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no management guidance, business outlook, risk update, contingency disclosure, or unusual operating item. The principal disclosed event is Pfizer’s reported 32.0% voting position in Haleon.
Important Facts to Verify
- Confirm whether the 32.0% position reflects Pfizer’s direct economic ownership, nominee-held securities, or both; the filing lists Guaranty Nominees Limited and Wealth Nominees Limited as shareholders.
- Verify the applicable threshold and the change from Pfizer’s previous notification, which is blank in the submitted text.
- Confirm the treatment and conversion ratio of the 591,012,724 restricted ADRs.
- Review subsequent ownership notifications for changes after July 17, 2022.